GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Net Change in Cash

GeneThera (GeneThera) Net Change in Cash : $0.00 Mil (TTM As of Sep. 2022)


View and export this data going back to 2000. Start your Free Trial

What is GeneThera Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

GeneThera's Net Change in Cash for the three months ended in Sep. 2022 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil.

GeneThera Net Change in Cash Historical Data

The historical data trend for GeneThera's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera Net Change in Cash Chart

GeneThera Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 -0.16 - -0.01 -

GeneThera Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GeneThera Net Change in Cash Calculation

GeneThera's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.009+0+0.009+0
=0.00

GeneThera's Net Change in Cash for the quarter that ended in Sep. 2022

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0.006+0+-0.006+0
=0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneThera Net Change in Cash Related Terms

Thank you for viewing the detailed overview of GeneThera's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneThera (GeneThera) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Net Change in Cash
Comparable Companies
NMTRQ CNBX RSPI CALA QBIO USRM IVRN PPCB CLCS RGIN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 SGEN XBRU:ARGX BNTX HKSE:02269
Traded in Other Exchanges
N/A
Address
3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035
Website
http://genetherainc.com
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Executives
Avel Kolesnikov director 11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr 10 percent owner 632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd 10 percent owner CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner director, officer: Chief Financial Officer 728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici director, 10 percent owner, officer: Chief Executive Officer 3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry director, 10 percent owner, officer: Chief Administative Officer 11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines